The Weekly Wire
A weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next.
A Washington University team solved six cryo-EM structures showing ketamine and PCP bound directly inside the same pocket opioid drugs occupy, not adjacent to it. The finding gives years of behavioral and pharmacological evidence linking ketamine to opioid receptors a direct molecular basis, and it revises a specific claim from the field's own foundational paper on the question.
Across this desk's coverage this year, CNS and psychiatric trials have repeatedly appeared as completed in registry records while their results remained publicly unavailable. That gap has a name, a legal deadline attached in some cases and none in others, and a compliance record that varies by a factor of five depending on who ran the study. None of it means a trial failed. Almost none of it means nothing.
Executive Order 2026-037 creates a scientific advisory committee to study whether Puerto Rico should build a pilot clinical research program for emerging therapies, including psilocybin, MDMA, and ibogaine, with veterans named as a priority population. The order explicitly does not authorize any clinical use of these compounds, a distinction worth stating plainly before the headline runs ahead of it.
Fibromyalgia sits entirely outside ketamine's labeled indications, and formulary and prior-authorization decisions for this off-label use have rested on studies of 34 patients or fewer. A new 92-patient retrospective with two years of follow-up is the largest and longest such dataset yet, and it shows both a durable benefit for some patients and a hard ceiling on how many respond at all.
More from pharma →The first peer-reviewed safety and outcomes data from a state-licensed psilocybin program shows strong results: most participants reported benefit, few serious adverse events, and real symptom reductions at three months. The data arrives in the middle of an Oregon Health Authority rulemaking process weighing fee increases that operators say could shut the program down.
More from psychedelics →DEA and HHS have moved to temporarily schedule concentrated 7-hydroxymitragynine while explicitly leaving natural kratom leaf alone, using a numeric potency threshold instead of a categorical ban. Where that threshold finally lands, and how it is measured, will determine how much of the existing kratom market ends up scheduled; the public comment window on it closed July 31.
More from cannabis →No regulator currently certifies whether an AI chatbot is safe to use for mental health support. NAMI's expanded partnership with digital psychiatry researcher John Torous, and the live MindBench.ai platform it has already produced, is building that evaluation infrastructure directly, ahead of any formal regulatory framework.
More from digital health →Last updated Aug 12, 2026
Postpartum depression
Updated Apr 18, 2026
Major depressive disorder
Updated May 9, 2026
Treatment-resistant depression
Updated Feb 27, 2026
Schizophrenia
Updated May 15, 2026
ADHD (adults and children 6+, at least 20 kg)
Updated Jul 24, 2026
Major depressive disorder
Updated Jun 15, 2026
Schizophrenia
Updated Jan 22, 2026
Treatment-resistant depression
Updated Jul 8, 2026
Major depressive disorder
Updated Jun 23, 2026
Generalized anxiety disorder
Updated Aug 12, 2026
PTSD
Updated Jun 6, 2025
Major depressive disorder
Updated Jul 2, 2026
Treatment-resistant depression
Updated Mar 5, 2026
Treatment-resistant depression
Updated Jul 16, 2026
Postpartum depression
Updated Feb 23, 2026
PTSD
Updated Jun 12, 2026
Epilepsy; behavioral indications explored
Updated Feb 14, 2026
Fragile X syndrome
Updated Feb 24, 2026
Major depressive disorder (adjunct)
Updated Apr 4, 2026
Schizophrenia (negative symptoms)
Updated Apr 9, 2026
Insomnia and anxiety
Updated Jan 12, 2026
Cancer pain, chronic pelvic pain, phantom limb pain, fibromyalgia, migraine: psilocybin trials are now running across a genuinely wide swath of chronic pain medicine. Nearly all of them share the same structural weakness, a pain-scale endpoint that cannot tell whether the drug changed the pain itself or changed how much the pain bothers the patient. That distinction is the entire story.
A retrospective study of 19 patients treated under Switzerland's limited medical-use exemption is among the first real-world psilocybin outcome data generated outside a clinical trial. The response and remission rates land close to what ordinary antidepressants achieve in real-world use, not the dramatic figures the field's early trials reported.
A retrospective analysis of 3,041 Mindbloom patients reports high rates of clinical improvement from at-home subcutaneous ketamine, a genuinely under-studied delivery route. The topline numbers are real. So is the conflict of interest, the near-total attrition by the final assessment, and the gap between the headline improvement rate and the much lower remission rate underneath it.
Track regulation, market movement, pipeline status, and news signals across pharma, psychedelics, cannabis, and digital health.
Plain-language context behind the industry headlines — no jargon, no hype.
What the trials actually show, where the FDA stands, and what "breakthrough" does and doesn't mean.
Read the coverage →New antidepressants, postpartum drugs, and fast-acting options — and why approval doesn't equal access.
Read the coverage →Telehealth, therapy apps, and AI tools — what's regulated, what works, and what to watch for.
Read the coverage →Free, confidential crisis lines and guidance on finding real care — available 24/7.
Get help →